Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256632 · ClinicalTrials.gov registry record · NA
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
A NA study of Choroidal Neovascularization, sponsored by Vision Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT01256632 is a NA study of Choroidal Neovascularization that has completed, run by Vision Research Foundation. The registered enrollment target is 40 participants, below the 180-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01256632, a NA study of Choroidal Neovascularization, has completed, sponsored by Vision Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective: \*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: * To measure the mean change in visual acuity from Baseline to Month 12. * To measure the mean change in central retinal thickness per OCT from Baseline to Month 12
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
Michigan
- Vision Research Foundation - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01256632
The ClinicalTrials.gov registry entry for NCT01256632 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 7 other Choroidal Neovascularization trials with a reported enrollment target (78% lower). The listed sponsor is Vision Research Foundation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroidal Neovascularization appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01256632 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01256632 about?
NCT01256632 is a clinical study titled "Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy". The primary objective: \*To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group. Secondary Objective: * To measure the mean change in visual acuity from Baselin...
What is the current status of trial NCT01256632?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2007-10. Estimated completion is 2010-10.
What conditions does trial NCT01256632 study?
This clinical trial studies the following conditions: Choroidal Neovascularization.
What interventions are being tested in trial NCT01256632?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01256632?
This trial is sponsored by Vision Research Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01256632 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Neovascularization
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
COMPLETED · Phase 1
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.